From idea to practice.

Apart from its own patent-protected technology platform, the Swiss pharmaceutical company InnoMedica is defined above all through the will of a team to develop from innovative research in the field of nanotransport systems and to bring them to patients. To achieve this goal, experienced entrepreneurs and managers work side by side with university graduates and young talents. Only the joint efforts of employees, investors, physicians and ultimately patients will make it possible to master the path to a prescription drug.

About InnoMedica

What started as a start-up with a founding team of five key people has evolved into a pharmaceutical company with its own certified Nanofactory and over 50 employees.

Team

Experienced entrepreneurs and scientists work together to bring InnoMedica's innovative medicine to patients in the shortest possible timeframe.

Investors

InnoMedica has developed into a public company in recent years. Through annual share offerings the shareholder base has grown to more than 1400 shareholders.

Job & Career

A team of creative thinking innovators combined with expertise and patient proximity. Apply now and actively contribute to the company's future success.

Media reports

Here you will find a selection of media coverage on InnoMedica and our projects.

Statements

Statements on Our Work

News

Most Recent Updates

May 2022

Parkinson trial and internationalization

NEON trial: Dose escalation completed – Parkinson’s patients want to continue treatment with Talineuren. The first …

Read more

March 2022

Stéfan Halbherr and InnoMedica receive CLINAM Award

CLINAM Award 2022 for special achievements in nanomedicine for Stéfan Halbherr and InnoMedica The Scientific Committee of …

Read more

March 2022

Update Talineuren and Capital Increase 2022

First Parkinson’s patients in the NEON study treated with Talineuren On December 14, 2021, the clinical …

Read more